Please note that this product (marketed as Vitrakvi) was withdrawn from the Community Register of designated orphan medicinal products in July 2019 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.
On 19 November 2018, orphan designation (EU/3/18/2097) was granted by the European Commission to Bayer AG, Germany, for larotrectinib for the treatment of glioma.
|Disease / condition||
Treatment of glioma
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.